Synced daily from ClinicalTrials.gov via AACT. Last sync: .
16 Elafibranor clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 13 indications (including Pharmacokinetics & Primary Sclerosing Cholangitis) and 3,353 total planned enrollment. 6 Phase 3 Elafibranor trials and 4 Phase 2 are listed. 2 Elafibranor clinical trials are actively recruiting at 29 U.S. sites across 13 states. Most recent activity: NCT06730061 (Apr 2032).
Where to Participate: All Elafibranor Trial Sites in the U.S. (29 sites across 13 states)
Every actively recruiting Elafibranortrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT02704403terminatedPhase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT03953456terminatedStudy to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
NCT03883607terminatedElafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
All Elafibranor trials (16)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
16 Elafibranor clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 7 are marked completed.
Are Elafibranor clinical trials recruiting in 2026?
Yes — 2 Elafibranor trials are actively recruiting in 2026, with 29 U.S. sites across 13 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Elafibranor being studied for?
Elafibranor is being studied for Pharmacokinetics, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Primary Biliary Cholangitis (PBC), Healthy Volunteers and 13 more. The trials are grouped by indication on this page.
What phase is Elafibranor in?
Elafibranor clinical trials span 6 Phase 3, 4 Phase 2, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Elafibranor clinical trials?
The lead sponsor across the most Elafibranor trials is Genfit, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Elafibranoras an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.